In This Issue: The Complexity of Genetics in Heritable Skin Diseases  by Richard, Gabriele & Uitto, Jouni
See related articles on pages 99, 103, 268 and 270
In This Issue: The Complexity of Genetics in Heritable
Skin Diseases
Gabriele Richard and Jouni Uitto
Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
Another curve ball: Autosomal recessive
erythrokeratodermia variabilis (EKV)?
Over the past decade, with the advent of molecular genetics
in general and completion of the Human Genome Project in
particular, spectacular progress has been made in under-
standing the genetic basis of a number of heritable skin
diseases. Mutations have now been identified in close to
200 distinct genes important for development and func-
tion of human skin, and in many cases explain the cutane-
ous manifestations associated with these disorders (see
Pulkkinen et al, 2002). This knowledge has provided novel
means for an updated and refined classification of gen-
odermatoses on molecular and etiological grounds, for
widespread availability of molecular diagnostic tests, pre-
natal diagnosis and improved genetic counseling, as well as
for the development of new therapeutic approaches (Uitto
et al, 2002). Nevertheless, molecular genetics alone is not
the ‘‘silver bullet’’ solving all diagnostic problems and patho-
genetic mysteries. As more genetic information is gathered,
the reliable classification of some disorders seems to be-
come more difficult, as in the case of erythrokeratodermas,
and genotype–phenotype correlations may be complex, as
illustrated by cutaneous connexin 26 disorders.
In this issue, two letters argue the pros and cons of au-
tosomal recessive EKV and highlight some of the funda-
mental problems of molecular genetic studies in rare
genodermatoses. In response to a recent publication by
Terrinoni et al (2004), which reported only the second family
with autosomal recessive EKV because of a novel missense
mutation in the connexin 31 gene (GJB3), van Steensel and
van Geel (p. 268) question the validity of the clinical diag-
nosis and the pathogenicity of the connexin 31 mutation in
lieu of functional studies of the mutant protein. The latter
authors’ comments underscore the scarcity of solid diag-
nostic criteria for EKV and the difficulties encountered even
by experienced dermatologists in distinguishing EKV from
other disorders with similar or overlapping features, such as
progressive symmetric erythrokeratoderma, localized (abor-
tive) forms of non-bullous congenital ichthyosiform ery-
throderma, or epidermolytic hyperkeratosis with cyclic
ichthyosis. In their invited response, Terrinoni and Melino
(p. 270) provide convincing clinical and histological infor-
mation supporting the diagnosis of EKV in their family, and
additional molecular data exclude a causative mutation in
the keratin 1 gene, refuting the diagnosis of epidermolytic
hyperkeratosis with cyclic ichthyosis. Nevertheless, the ob-
servations on patients with overlapping or new, distinctive
features, together with reports of mutations in different
genes (connexins, loricrin, transglutaminase 1) resulting in
erythrokeratodermas as well as other disorders of cornifi-
cation, have fueled recent debates on the classification
and nomenclature of erythrokeratodermas (Hohl, 2000;
van Steensel, 2004). Yet, a complex understanding of the
different erythrokeratoderma phenotypes and their etiology
beckons further thorough clinical and molecular analyses
in larger cohorts of patients. With the mounting evidence
provided by Terrinoni et al (2004) and Gottfried et al (2002)
that pathogenic connexin 31 mutations may be inherited
in an autosomal recessive fashion, nature has thrown
us another curve ball, challenging our emerging under-
standing of the pathological mechanisms of cutaneous gap
junction disorders.
Psoriasis: The elusive candidate genes
Following the success in identifying distinct mutations in the
candidate genes in an increasing number of single-gene
Mendelian disorders, the emphasis has been shifting to-
ward analysis of complex genetic traits. The goal of these
studies is to identify susceptibility or protective genes
through association studies and genetic linkage analyses.
The paradigm of such conditions is psoriasis, a relatively
common disorder with multifactorial etiology. Although es-
timates have suggested that the overall heritability of pso-
riasis may be as high as 90%, it is clear that there are
environmental factors needed for the expression of the
phenotype.
A number of genome-wide linkage studies have been
performed in attempts to identify putative susceptibility loci
in psoriasis, and there is now a consensus that a chromo-
somal region of  250 kb, termed risk haplotype 1 (RH1),
on the short arm of chromosome 6, harbors a psoriasis-
associated locus designated as PSORS1. This region con-
tains the HLA-C major histocompatibility locus as well as at
least two candidate genes; HCR (encoding an a-helical
coiled coil rod) and CDSN (encoding corneodesmosin). In
addition to PSORS1, putative linkage has been established
to eight additional loci (PSORS2-9) dispersed throughout
the human genome. However, the precise identification of
the susceptibility gene(s) is lacking.
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In this issue, two articles deal with psoriasis genetics.
First, Allen et al (p. 103) have looked into the role of PSORS1
in genetic susceptibility to late-onset psoriasis (LOP), as
defined by the onset of the disease after 40 years of age.
Genotyping for HLA-C alleles and a number of single nuc-
leotide polymorphisms within the HCR and CDSN candi-
date genes demonstrated only a weak association to
PSORS1 locus, and analyzing patients with the onset be-
yond 50 years of age provided no evidence of association at
all. Thus, PSORS1 is not a major genetic risk factor in the
pathogenesis of LOP. This somewhat surprising finding
raises several questions: First, is the early-onset psoriasis
and LOP etiologically one and the same disease, or are we
dealing with genetically distinct subsets of this clinical dis-
order? In fact, LOP is typically sporadic, and therefore, the
degree of genetic component is largely undefined. Second,
could it well be that early-onset and late-onset forms of
psoriasis just represent clinical phenocopies because of
entirely different pathoetiologic mechanisms? The authors
suggest that an ‘‘instructive way to discriminate type I and
type II psoriasis may be to separate them according to their
association with PSORS1’’. Whether such distinction proves
informative in assessing future patient treatment, as sug-
gested by the authors, awaits completion of clinical trials
that would test the hypothesis that the genetic contribution
to psoriasis can predict the individuals’ response to a spe-
cific treatment modality.
The second paper dealing with psoriasis genetics, by
Foerster et al (p. 99), embarks on re-evaluation of a previ-
ously published data set (Nair et al, 2000) by haplotype
sharing analysis, with particular reference to the marker
M6S168. Their findings confirm localization of the PSORS1
locus to the RH1 region, a finding that could be replicated in
an independent cohort. A computer search of the candidate
region revealed residual fragments of the human endo-
genous retrovirus K (HERV-K) family, depicting two open-
reading frames, one of them corresponding to a retroviral
dUTPase. Interestingly, nucleotide polymorphisms predict-
ed amino acid variations between the high-risk and the low-
risk pools. The authors point out, however, that although the
expression of the corresponding DNA segments could be
demonstrated by RT-PCR in peripheral blood cells as well
as in normal and lesional psoriatic skin, it is uncertain
whether the deduced protein is enzymatically active. This
led the authors to speculate that the presence of low level of
dUTPase activity could lead to viral persistence or replica-
tion. Alternatively, the authors suggest that perhaps the
non-functional PSORS1-derived dUTPase may contribute
to psoriasis pathogenesis as a dominant-negative protein or
auto-antigen. Although these are interesting possibilities,
there is no proof to suggest that these retroviral remnants
imbedded into the human genome have any role in the ex-
pression of the psoriatic phenotype.
It is interesting to note that the paper by Foerster et al
has 16 co-authors who re-analyzed haplotype data previ-
ously published by others. This approach reflects the fact
that use of refined, more sophisticated statistical analyses,
especially when extended to larger, multiethnic population
groups, allows perhaps more accurate assessment of the
PSORS1 locus. In this context, it is of interest that a recent
paper submitted to JID, dealing with PSORS1 locus in pso-
riasis, had 30 authors, and the conclusions largely refuted
some of the authors’ previous findings. This certainly is a
way to beef up the bibliography in your CV!
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